Peripheral Opioid Receptor Agonists for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly those involving opioid analgesics, are limited by significant drawbacks such as inefficacy, tolerance, and chemical dependence, along with undesirable central nervous system-mediated side effects.
Innovation Solution
Development of compounds, such as those represented by Formulas I, II, III, and IV, which act as μ-opioid receptor agonists, offering a pharmacological approach to treat various types of pain while minimizing side effects by modulating the opioid receptor system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioid analgesics are used to treat pain, then pain relief is achieved, but CNS-mediated side effects occur
Solution Approach 1:
The patent segments the opioid receptor system into peripheral and central components, designing compounds that selectively target peripheral opioid receptors (OPRMs) located on sensory neurons. This spatial segmentation allows pain relief through peripheral mechanism while avoiding central nervous system penetration and associated side effects
Solution Approach 2:
The invention applies local quality by creating compounds with selective affinity for peripheral opioid receptors versus central opioid receptors. The molecular structure is designed to interact specifically with peripheral OPRMs on nociceptive neurons, providing localized pain relief without affecting central brain regions that mediate respiratory depression, euphoria, and dependence
2Reliability
If traditional opioid therapies are used, then pain management is provided, but tolerance and chemical dependence develop
Solution Approach 1:
The patent introduces peripheral opioid receptors as an intermediary mechanism for pain relief. By activating peripheral OPRMs on sensory neurons rather than directly acting on central opioid systems, the compounds provide an alternative pathway that achieves analgesia without triggering the central adaptive responses that lead to tolerance and dependence
Solution Approach 2:
The invention extracts the pain relief function from the central opioid system and relocates it to the peripheral nervous system. By isolating the therapeutic effect to peripheral OPRM activation, the patent removes the problematic central-mediated outcomes of tolerance and chemical dependence while preserving the beneficial analgesic effect
Data Source
AI summary
Provided herein are compounds that are useful in the treatment of pain in a subject.